FOLD
Amicus Therapeutics Inc

6,333
Loading...
Loading...
News
all
press releases
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
Zacks·7d ago
News Placeholder
More News
News Placeholder
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
Zacks·13d ago
News Placeholder
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy
Amicus Therapeutics (FOLD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·14d ago
News Placeholder
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
Zacks·14d ago
News Placeholder
Zacks.com featured highlights include Amicus Therapeutics, Micron Technology and General Dynamics
Zacks highlights Amicus Therapeutics, Micron Technology, and General Dynamics as top picks with upgraded broker ratings and strong earnings outlooks.
Zacks·14d ago
News Placeholder
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns
Broker upgrades fuel optimism for Amicus Therapeutics, Micron and General Dynamics as earnings outlook strengthens.
Zacks·15d ago
News Placeholder
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.
Zacks·19d ago
News Placeholder
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Zacks·26d ago
News Placeholder
Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock?
Atara Biotherapeutics (ATRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·26d ago
News Placeholder
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·1mo ago

Latest FOLD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.